Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.510
-0.040 (-2.58%)
Apr 25, 2025, 12:07 PM EDT - Market open
Sunshine Biopharma Revenue
In the year 2024, Sunshine Biopharma had annual revenue of $34.87M with 44.75% growth. Sunshine Biopharma had revenue of $9.59M in the quarter ending December 31, 2024, with 24.93% growth.
Revenue (ttm)
$34.87M
Revenue Growth
+44.75%
P/S Ratio
0.03
Revenue / Employee
$670,659
Employees
52
Market Cap
5.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.87M | 10.78M | 44.75% |
| Dec 31, 2023 | 24.09M | 19.75M | 454.42% |
| Dec 31, 2022 | 4.35M | 4.12M | 1,802.41% |
| Dec 31, 2021 | 228.43K | 157.02K | 219.88% |
| Dec 31, 2020 | 71.41K | 50.29K | 238.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SBFM News
- 4 days ago - Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion - Accesswire
- 22 days ago - Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - Accesswire
- 22 days ago - Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Accesswire
- 23 days ago - Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Benzinga
- 23 days ago - Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer - Accesswire
- 23 days ago - Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year - Accesswire
- 4 weeks ago - Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada - Accesswire
- 6 weeks ago - Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - Accesswire